Costly Second-Gen TKIs For CML Patients
Published: 2020-10-13 |
Author: Christina Bennett, MS |
Source: Oncology Nurse Advisor
Most patients with chronic myelogenous leukemia (CML) are being prescribed costly second-generation tyrosine kinase inhibitors (TKIs), even though generic imatinib has been available since 2016, found a recent study in JAMA Oncology.
The study included patients with CML diagnosis who initiated treatment with TKI between January 1, 2010, and December 31, 2019, and were identified using the database OptumLabsData Warehouse. Medical and pharmacy claims data were extracted from the database for patients with commercial insurance and Medicare Advantage.
For their first year of TKI treatment only 19% of patients started by filling a prescription for a second or third-generation TKI in 2010, and by the end of the year this number was 34%. In contrast, in 2019, more than half of patients (56%) started their treatment by filling a prescription for a second-or third-generation TKI even with generic imatinib being available.
"Despite the lack of evidence for an overall survival difference between first-or second-generation TKIs, most patients with CML are now prescribed a second-generation TKI in the US," the study authors wrote.